Marizomib, a proteasome inhibitor, has shown anti‐tumour activity in NSCLC and, when combined with HDAC inhibitors, synergistically enhances cellular stress and promotes cancer cell apoptosis [71]. Here, HDAC9 is linked to non-small cell lung carcinoma.